Will manufacture and export but not sell weight-loss drug in India, Dr. Reddy's tells Delhi HC
Dr. Reddy's Laboratories Ltd. and OneSource Specialty Pharma have given an undertaking before the Delhi High Court that they will neither sell nor market Novo Nordisk's anti-obesity drug Wegovy within India pending the outcome of a patent infringement lawsuit filed by the Danish pharmaceutical giant.
The case concerns an alleged violation of Novo Nordisk's patent on its diabetes medication, semaglutide.
Dr. Reddy's and OneSource, represented by senior advocates Abhishek Manu Singhvi and Mukul Rohatgi, respectively, informed the court that while Dr. Reddy's has been granted a licence to manufacture the contested drug in December 2024 and began production in April 2025, Dr. Reddy's currently does not hold a licence to sell the drug in India.
Dr. Reddy's and OneSource gave an assurance that they will will not sell the drug in India. However, the Indian parma companies said they reserve their right to export the drug in countries where Novo Nordisk has not been granted a patent yet.
These submissions were formally taken on record by the court, and the counsel for two pharma companies confirmed that the undertaking would remain binding on the company until the next hearing.
Appearing for Novo Nordisk, senior advocate Sandeep Sethi argued that under the Indian Patents Act, 1970, even exporting a product that infringes a patent constitutes an act of infringement.
The court, in its May 29 order, said it will consider the submission of the parties on the next date of hearing, on August 19.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
32 minutes ago
- Economic Times
Niva Bupa shares fall 11% as PE investor sells 12% stake in block deal
Shares of Niva Bupa Health Insurance slipped as much as 11.1% on Monday to Rs 82 on the BSE after a large block deal involving a 12% equity stake saw 56.3 lakh shares change hands, as per ETNOW. ADVERTISEMENT Ahead of the trade, on June 1, ET NOW reported, citing sources, that homegrown private equity firm True North and Niva Bupa's Managing Director and CEO, Krishnan Ramachandran, were set to offload a combined 132 million shares in the health insurer through a block deal. ETNOW had also reported that Fettle Tone LLP, an investment vehicle of True North, was expected to sell up to 122 million shares, or roughly 6.7% of Niva Bupa's equity. CEO Krishnan Ramachandran was likely to dilute 10 million shares, equating to around 0.5% of the company. The offer price was set at Rs 82 per share, pegging the total size of the transaction at around Rs 1,082 crore. Based on the latest shareholding pattern as of March-end, the company's promoter Bupa holds 55.98% stake, while True North holds 17.47% via Fettle Tone Bupa reported a 31.2% year-on-year rise in net profit for the March quarter, posting Rs 206 crore compared to Rs 157 crore in the same period last year. Gross premiums increased 18% to Rs 2,078.7 crore, while net premiums climbed 21% to Rs 1,672 the insurer's underwriting profit slipped 12.2% year-on-year to Rs 57.6 crore from Rs 65.6 crore. Operating profit also fell sharply by 43.1% to Rs 94.9 crore from Rs 166.8 crore in the year-ago period. Its solvency ratio stood steady at 3.03% on a sequential basis. ADVERTISEMENT Niva Bupa Health Insurance listed on Indian stock exchanges in November 2024, marking the first domestic listing of a pure-play global MNC health insurer backed by British firm Bupa. In September 2023, True North ceded control to Bupa by selling a 20% stake for approximately Rs 2,700 crore. Also read | Ircon International shares jump over 2% after winning Rs 1,068 crore EPC contract from railways (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
New Indian Express
32 minutes ago
- New Indian Express
Equity markets are poised to open higher as strong GDP data lifts investor sentiment
CHENNAI: Indian equity markets are poised to open higher on Monday, June 2, following stronger-than-expected GDP data that has lifted investor sentiment. The Gift Nifty was trading at 24,841.5 as of 8:07 AM, indicating a positive opening for benchmark indices, with Nifty 50 likely to open above Friday's close of 24,750.7. India's GDP expanded by 7.4% in the fourth quarter (January–March), outperforming consensus estimates. The growth was largely fueled by robust activity in the construction and manufacturing sectors, suggesting underlying strength in industrial demand and infrastructure spending. This upbeat data has reinforced confidence in the domestic economic recovery and is likely to drive early market gains. Sectors in Focus: Banking and Financials: Traders are closely watching rate-sensitive stocks as the Reserve Bank of India's monetary policy decision approaches later this week. Expectations are that the RBI may maintain its current stance while monitoring inflation trends. Auto and Real Estate: Both sectors stand to benefit from economic momentum and expectations of continued policy support. Auto sales data for May, set to be released during the week, could further influence investor sentiment. Construction & Capital Goods: Stocks in these sectors may see renewed buying interest following the GDP report highlighting their contribution to growth. Global cues remain mixed, with US markets ending Friday slightly higher amid speculation on the Federal Reserve's rate path. Asian markets opened cautiously today, reflecting global macro uncertainties, but India's domestic narrative remains more optimistic. Key Levels to Watch: Nifty 50: Immediate resistance seen near 24,900; support at 24,650 Sensex: May track similar gains, eyeing new all-time highs Investors will also keep an eye on foreign institutional inflows, corporate commentary, and macro updates through the week, including the upcoming RBI policy meet and US payroll data.
Economic Times
32 minutes ago
- Economic Times
Nykaa shares drop despite strong Q4 performance
Nykaa parent FSN E-commerce saw shares decline in early trade as Indian market opened with losses on Monday. The counter opened 2% lower at Rs 199 against the previous closing of Rs 203.26 on the BSE. It was trading at Rs 201.26 as of 9:53 am. The beauty and fashion retailer posted strong March quarter numbers last Friday, with nearly doubling to Rs 19 crore. The Mumbai-based company's operating revenue rose 23.6% year-on-year to Rs 2,016.7 crore for the fourth quarter, up from Rs 1,667.9 crore, driven by customer acquisition, brand partnerships, and network expansion. The performance was in line with the company's guidance issued in April, when it projected consolidated net revenue growth in the low to mid-20% range for the March on a sequential basis, Nykaa's Q4 profit declined 29.3% from Rs 26.9 crore reported in the previous quarter. Nykaa's beauty vertical, which contributes over 90% of the company's total revenue, posted a 24.7% YoY increase to Rs 1,895 crore from Rs 1,519 crore. The fashion segment saw muted growth, rising 11% to Rs 161 crore from Rs 145 crore, with gross merchandise value (GMV) growing 18% year-on-year. For the full fiscal year, Nykaa reported a consolidated gross merchandise value (GMV) – total value of goods sold across its platforms – of Rs 15,604 crore, a 25% increase from the previous year. Nykaa currently serves 42 million customers and operates 237 offline stores across India, offering products from over 8,600 brands. In FY25 alone, the company added around 50 stores — its highest annual addition to date."While BPC segment continues to deliver healthy growth with better profitability, revival in fashion business remains a key monitorable, given the heightened competitive intensity across the industry," said brokerages house Nuvama in a note on Monday. Nuvama analysts continue to expect improvement in profitability on the back of lower losses in fashion and eB2B segment.
